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The optimization of healing processes in a wide range of tissues represents a central point for surgical research. One approach is to
stimulate healing processes with growth factors. These substances have a short half-life and therefore it seems useful to administer
these substances locally rather than systemically. One possible method of local delivery is to incorporate growth factors into a
bioabsorbable poly (D, L-lactide) suspension (PDLLA) and coat suture material. The aim of the present study was to establish a
procedure for the local delivery of growth factors using coated suture material. Sutures coated with growth factors were tested in
an animal model. Anastomoses of the colon were created in a rat model using monoﬁlament sutures. These were either untreated
or coated with PDLLA coating alone or coated with PDLLA incorporating insulin—like growth factor-I (IGF-I). The anastomoses
were subjected to biomechanical, histological, and immunohistochemical examination. After 3 days the treated groups showed
a signiﬁcantly greater capacity to withstand biomechanical stress than the control groups. This ﬁnding was supported by the
results of the histomorphometric. The results of the study indicate that it is possible to deliver bioactive growth factors locally
using PDLLA coated suture material. Healing processes can thus be stimulated locally without subjecting the whole organism to
potentially damaging high systemic doses.
1.Introduction
In spite of considerable progress in operating techniques,
the use of histocompatible materials, and minimally invasive
operating procedures, healing processes following surgery
arefrequentlydisturbed. Thismeansthattheoptimisation of
healing processes in a wide variety of tissues is a central topic
for surgical research. Healing processes can be upset by many
diﬀerent factors such as prior illness, old age, inadequate
nutrition, immune suppression, or sepsis. Current initiatives
in surgical research are therefore seeking methods by which
healing processes can be stimulated.
The use of growth factors opens up an entirely new range
of possibilities for stimulating healing processes and has
demonstrated to stimulate cell growth in a variety of tissues
[1–5] that could lead to further improvement of healing
processes and reduction of complication rates. Shorter hos-
pital stays and ﬁnancial savings would be another aspect.
Further positive side eﬀects would be the reduction of
(a) nosocomial infections, (b) pneumonia resulting from
immobilisation, and (c) deep leg vein thrombosis with the
associated risk of lung embolisms (lethality 5%).
Growth factors are small proteins which act as mediators
withincellsandthusinﬂuencecelldivision,growth,diﬀeren-
tiation, and protein synthesis. They are present in plasma at
extremelylowconcentrationsandprobablyregulateallorgan
systems.
So far growth factors have been used systemically [6],
either by the additional implantation of carriers in the form
of collagen sponges [7], with catheters, by injection, or in
nutritional supplements [8, 9]. These techniques yielded
demonstrable eﬀects on the healing of bone, cartilage, and
tissues in the gastrointestinal tract, but they did not appear
practicable for clinical use. It seems useful to concentrate
eﬀorts on developing suitable systems for delivering them2 The Scientiﬁc World Journal
locally without subjecting the whole organism to high sys-
temic doses.
Such local delivery systems need to enable the sub-
s t a n c et oa c ta n dt oe n s u r eas u ﬃcient level of biological
activity for optimal eﬀects. The carrier materials must be
bioabsorbable [10] and biocompatible to minimize immune
reactions, toxicity, and side eﬀects. Neither locally induced
inﬂammatory reactions nor physical blocking as a result
of incomplete metabolism can be allowed to inhibit the
healing process. The carrier materials must be sterilizable
and permit ﬂexibility in the amounts of the substances being
delivered. The incorporated substances need to be released
in a continuous and controlled manner so that they are
not absorbed before exerting their eﬀects. A high level of
user friendliness and easy handling are also desirable for the
operating surgeons [10].
A procedure has therefore been developed and brought
into use that turns implants into drug carriers. Using these
implants, substances can be placed where required and re-
leasedinacontrolledmannerwithoutcausingsystemicstress
to the organism. A biodegradable surface coating based on
poly (D,L-lactide), PDLLA, was developed for this purpose.
Bioactive substances such as growth factors can be incorpo-
rated into this coating [11, 12].
Poly (lactides) and poly(glycolic acids) and their co-
polymers are widely available biomaterials and can be used
as drug carriers [10, 11, 13] .T h ep r o p e r t i e so ft h eP D L L A
c o a t i n gd e v e l o p e dw e r ei n v e s t i g a t e di nin vitro studies.
These included the thickness of the layer (about 10μm), its
ﬁrmness,itsdecompositiondynamicsinvivoandinvitro,the
release kinetics of the incorporated growth factors, and their
stability in the coating.
One of the most frequently used procedures for the re-
construction of damaged tissue is suturing. We set out to
develop a procedure for coating suture material with growth
factors without altering properties such as absorbability,
tissue tolerability, and handling.
Suture insuﬃciency following intestinal resection is one
of the most severe complications in gastrointestinal surgery.
The rate of clinically signiﬁcant anastomotic insuﬃciency
following colon resection is still between 3.4 and 8% [14, 15]
in spite of progress in anastomosis techniques. In the clinical
setting suture insuﬃciency with development of peritonitis
is diagnosed primarily in the early postoperative phase (day
1–day 10) and leads to abscesses and ﬁstulae. In various
experimental models, the positive inﬂuence of endogenous
growth factors on wound healing has been shown [6,
14–18]. The biological actions of these growth hormones
include mitogenic [4, 18, 19] or chemotactic eﬀects [20],
release of cytokines [4], stimulation of angiogenesis [4]
and improvement of extracellular matrix production [21].
Systemic keratinocyte growth factor (KGF) or insulin-like
growth factor 1 (IGF-1)—shown experimentally—leads to
improve anastomosis healing in rat colon [6, 18]. However,
as giving an excess of growth factors can have potentially
harmful eﬀects on the whole organism, methods should
be investigated by which growth factors can be applied at
deﬁned target areas in deﬁned quantities. A newly developed
technology makes this possible. The carrier material used
is a biodegradable PDLLA coating [11, 12]. The aim is to
improve the healing of anastomoses following colorectal re-
s e c t i o ni na na n i m a lm o d e li no r d e rt or e d u c et h er a t eo f
occurrence of anastomotic insuﬃciency and its sometimes
catastrophic consequences.
2.MaterialandMethods
2.1. Coating. In the process described here a bioabsorbable
polylactide coating PDLLA is applied to suture material in
a “cold” coating process to render incorporated substances
“biological active.” This process turns the implant itself into
a drug carrier.
The coating process takes place under clean room condi-
tions at room temperature and therefore also allows thermo-
labile substances to be incorporated without aﬀecting their
biologicalactivity[22].Themodiﬁablecoatingthicknesswas
investigatedusingscanningelectronmicroscopy.Thebiome-
chanical strength of coated and uncoated suture material
was tested by a load to failure test using a material testing
machine (Zwick).
For the rat anastomosis model, Ethicon 6/0 PDS sutures
(45cm long) were coated with 30μg rh-IGF-I per suture.
An in vitro elution test was carried out on suture materi-
alsoveraperiodof10days.Aprotininwasusedinthiselution
test. Aprotinin is a protein with a similar molecular weight
(approximately same size) as IGF-I.
2.2. Experimental Animals. Anastomoses were performed in
5-month-old female Sprague Dawley rats. Up to 24h before
and immediately after the operation, they had free access to
water and dry feed. The animal experiment was carried out
with the permission of the responsible authority (Landesamt
fur Arbeitsschutz, Gesundheitsschutz und technische Sicherheit
Berlin—Berlinstate oﬃcefortechnical safety and the protec-
tion of work and health), permit number G0045/01.
2.3. Operation. Dry feed was replaced with a special ﬁbre-
free feed 24h prior to the operation. The operation was per-
formed under general anaesthesia. Initial inhalation narcosis
used a mixture of oxygen, nitrous oxide, and isoﬂurane. A
mixture of ketamine hydrochloride (80mg/kg body weight)
and 2% xylazine (12mg/kg body weight) was then given by
intraperitoneal injection.
This anaesthetic mixture narcotised and anaesthetised
the experimental animals for about 90 minutes.
Blood samples were taken from the retrobulbar venous
plexus of the right eye. About 1.5mL of whole blood was
taken for the determination of serum and blood parameters.
Prior to the operation, the anaesthetised animals were
weighed and their rectal temperature was determined.
Each rat’s abdomen was shaved and then depilated. After
skin disinfection, a longitudinal laparotomy was performed.
The intestine was exposed under an operating microscope
up to the transverse colon, which was cut 1cm distal to the
hepatic ﬂexure. An end-to-end anastomosis was then created
using a continuous seromuscular suture with randomised
use of either coated or uncoated sutures. The anastomosisThe Scientiﬁc World Journal 3
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Figure 1: SEM images of uncoated (a) and coated (b) monoﬁlament sutures. The coating forms an smooth even layer of 10 μm thickness
in which growth factors can be incorporated.I nv i v othe PDLLA coating is hydrolyzed and the growth factors are released in their biological
active form.
was tested for leaks and luminal continuity prior to layered
closure of the abdominal wall (see Table 2).
Of the 16 animals in each group, 8 were subjected to
biomechanical evaluation and 8 to histological/immunohis-
tochemical evaluation.
Follow-up observation was carried out for 24h. Blood
samples were taken, and body core temperature was mea-
sured at day 3 and again at day 7 after surgery. The anasto-
mosis of the colon was evaluated biomechanically, histomor-
phometrically, and immunohistochemically.
2.4. Biomechanical Evaluation. Biomechanical evaluation
took the form of an intraluminal pressure stress test. For
each time point, n = 8 animals were investigated. The anas-
tomosis was subjected to stress using isotonic saline solution
delivered by a 4-roller pump. At the same time, the intra-
luminal pressure at the level of the anastomosis was derived
using a force transducer (Mammendorfer Institut). The data
were ampliﬁed and transferred to a computer with the aid
of the measurement data analysis programme Catman. The
maximum bursting pressure was evaluated in each case
(Figure 3). Eight animals per group were evaluated for each
time point. Statistical comparisons were made using the
nonparametric Wilcoxon-Mann-Whitney test as the data for
the individual groups were independent and not normally
distributed. The statistical software SPSS was used.
2.5. Histomorphometric and Immunohistochemical Evalua-
tion. After the animals had been killed (n = 8p e rg r o u p
for each time point), the anastomosis was dissected out. It
was separated 1cm proximally and distally, and the tissue
was ﬁxed. HE and Van Gieson stains were used for the
histologicalevaluation.Toanalysetheinﬂammatoryreaction
and angiogenesis, immunohistochemical investigations were
performed using CD68 antibodies, alpha smooth muscle
actin,andfactorVIIIstainsmoothmusclecellsandendothe-
lial cells.
Evaluations were randomised and carried out blindly. In
the area of the anastomosis, the connective tissue bridging
and reepithelisation were evaluated. Vascularisation was also
assessed and allocated a score. Inﬂammatory cells marked
with CD68 antibodies were also counted in the area of the
anastomosis. Reepithelisation was taken to be an indication
of functioning replacement tissue in the area of the anasto-
mosis.4 The Scientiﬁc World Journal
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Figure 2: For in vitro release tests aprotinin was used. aprotinin
is a protein with approximately same size as IGF-I. The aprotinin
concentration was measured over the time. After an initial peak, a
constant release over at least 10 day took place.
Granulation, reepithelisation, connective tissue bridging,
and revascularisation, as well as numbers of ﬁbroblasts, ne-
croses, and macrophages, were evaluated by a modiﬁed score
published by several authors [18, 23–25].
Tissue reaction (score):
( 1 )n oo rm i n o rr e a c t i o n
(2) poor reaction
(3) mean reaction
(4) strong reaction
Statistical evaluation was carried out using the Kruskal
Wallis test and the Mann-Whitney U test and later balanced
usingaBonferroni-Holmesadjustment.Thesigniﬁcancelev-
el was taken to be 0.05.
3. Results
3.1. Coating. Examination using a scanning electron micro-
scope showed the PDLLA layer on the sutures to be smooth
and even and about 10μm thick (Figure 1). In the elution
test, the proteins incorporated into the coating were released
at a constant rate over 10 days after an initial peak (Figure 2)
The biomechanical stress test showed no signiﬁcant diﬀer-
ence between the coated and uncoated sutures (n = 5p e r
group).
3.2. Clinical Evaluation. No diﬀerences in body temperature
or weight were found at any time in any of the groups.
Inﬂammatory cell counts were normal throughout.
3.3. Biomechanical Evaluation. No signiﬁcant diﬀerences in
bursting pressure were found between the groups 24 hours
after the operation (data not shown). However, three days
after the operation, the stability of the anastomosis in group
III (PDLLA + IGF-I) was signiﬁcantly higher than in the
Table 1: Analyses of the necrotic tissue reaction at the anastomoses
in between the groups at day 1, 3, and 7 after surgery. Signiﬁcant
less necroses were seen at day 3 and 7 in the IGH-I-treated group.
Necroses Day 1 Day 3 Day 7
Control group 1,0 ± 0,0# 3,4 ± 0,7 3,0 ± 0,9#
PDLLA group 1,4 ± 0,7 1,8 ± 0,7∗ 2,0 ± 1,3
IGF-I group 1,3 ± 0,7 2,0 ± 1,1∗ 2,0 ± 1,1
∗P<0.05 in between the control and PDLLA group; control and IGF-I
group at day 3;
#P<0.05 within the control group in between days 1 and 3; days 1 and 7.
Table 2: Experimental groups.
Group I uncoated sutures n = 16
G r o u pI I P D L L A - c o a t e ds u t u r e s n = 16
Group III PDLLA + IGF-I-coated sutures n = 16
control groups I (uncoated sutures) and II (PDLLA coated
sutures). After seven days the animals treated with coated
sutures impregnated with growth factors showed greater
biomechanical stability in the area of the anastomosis than
the control groups, but this diﬀerence did not achieve
signiﬁcance. The loss of stability in the control groups 3
days after the operation did not occur in the animals treated
with IGF-I. The bursting pressures reached after 3 days
in the growth-factor-treated animals were reached by the
PDLLA group only after 7 days. The anastomoses treated
with uncoated sutures did not reach this level of stability at
all during the experiment (Figure 4).
3.4. Histomorphometric and Immunohistochemical Evalua-
tion. Collagen synthesis increased over the period of time.
Lookingattheconnectivetissuebridgingoftheanastomosed
region over the time, an increased level of connective tissue
in the IGF-I treated group became obvious, even though
there was no signiﬁcant diﬀerence measurable at day one
and three but at day 7. This eﬀect due to locally applied
IGF-I might explain the increased mechanical stability at day
three after surgery, since the increase of connective tissue
was signiﬁcantly higher in the growth-factor-treated group
in between day one and three, but was not signiﬁcant in the
control groups (Figure 5).
Reepithelisation of the mucosa became obvious espe-
cially at day seven after surgery in all groups, and a tendency
of advanced reepithelisation was seen at this time point
in the IGF-I treated-group. In this group the increase of
reepithelisation became signiﬁcant already between day one
andthreeandthreeandseven,whereassigniﬁcantdiﬀerences
of reepithelisation in the control groups did not become
obvious until day seven after surgery (Figure 6).
Except in the uncoated group in the region of the anasto-
mosis at day three and day seven, necroses rarely were seen.
(SeeTable 1)EspeciallythecoatingandtheappliedIGF-Idid
not cause any side eﬀects, which lead to disturbance of the
surrounding tissue at any time point (Figure 7).The Scientiﬁc World Journal 5
Figure 3: For histologic examinations, the region of the anastomosis was dissected 2cm proximal and distal of the anastomosis. HE stains
and von Gieson stains were done to evaluate the anastomotic healing. The black arrow marks the suture material, and the white arrow marks
the anasotomosis.
4. Discussion
Coating of medical devices such as coronary stents [26, 27]
and catheters [28] or orthopaedic devices such as prostheses
[29, 30] and intramedullary nails [31] becomes of more and
more interest in modern medicine. Several studies describe
coating of suture material [32, 33] either to prevent infection
or to stimulate healing processes. Korenkov et al. applied
TGF-β1 into the abdominal wall to augment their strength
in rat hernia model, but there was no proof in increasing
strength in the TGF-β1-treated groups [34].
This study was able to show that it is possible to coat
suture material with growth factors and keep them biolog-
ically active after they are released out of the coating. It
could be shown that local application of IGF-I can improve
signiﬁcantly the healing of intestinal anastomoses in the rat
model. As well as ensuring the mechanical stability of the
anastomosis, coated suture material can thus function as a
drug carrier at the same time.
In our study we could show that coating suture material
with a bioabsorbable polylactide provides an opportunity
of delivering drugs locally in eﬀective concentrations. This
method is appropriate for a variety of indications and does
notaltertheprovenpropertiesofthesurgicalsuturematerial.
At the same time, no side eﬀects in means of disturbing
healing processes caused by the polylactide-coating were
seen. It even seems that using PDLLA coated sutures avoids
the occurrence of necrosis.
The rate of anastomotic insuﬃciency following colon
resection is between 3.4 and 8% [14, 15]. This rate of
occurrence could be reduced when using coated suture ma-
terial. Catastrophic consequences such as peritonitis and the
resulting of additional operations and long stays in hospital
could be reduced. Side eﬀects of locally applied IGF-I were
not seen in this study.
Ithasbeenshownthatintraperitonealorintracolicdeliv-
ery of IGF-I or KGF can lead to improved healing of colonic
anastomoses in an animal model [6, 18]. However, it has not
yet been possible to achieve limited local delivery of growth
factors. It has been found that expression of transforming
growth factor (TGF)-α and vascular endothelial growth fac-
tor (VEGF) is increased in carcinoma of the colon [35]. In
the light of this ﬁnding, it is particularly important to limit
release in terms of both time and space. The use of coated
suture material could oﬀer an innovative means to achieve
this. It opens up a new range of prophylactic options for
complications associated with anastomoses in patients with
reduced healing capacity, such as those with CED, or in
patientsreceivingimmunesuppressionfollowingtransplants
or had radiation before.
In summary, the coating process described here should
be seen as a key technology. The coating can be applied to a
wide variety of implants made from diﬀerent materials. The
appropriate drug can be delivered locally in a targeted and
individually tailored dose to treat the particular indication
or pathogenic spectrum. The method can be used either to
avoid giving high systemic doses, which may have negative
side eﬀects, or to provide local support for the systemic
action of substances such as antibiotics.6 The Scientiﬁc World Journal
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Figure 4: Statistical analyses of the bursting pressure tests showed
a decrease of stability three days after surgery in the control groups
(uncoated and PDLLA coated). This decrease was not seen in the
IGF-I-treated specimens. At day three after surgery, a signiﬁcant
higher bursting pressure was measured in this group compared
to the controls. 7 days after surgery no signiﬁcant diﬀerence was
seen in between the groups. Statistical analyses were performed
using ANOVA analyses and were adjusted with the Bonferroni test
(∗P ≤ 0.05).
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Figure 5: Collagen synthesis increased over the period of time and
therefore the amount of cellular connective tissue. Looking at the
connective tissue bridging of the anastomosed region over the time,
an increased level of connective tissue in the IGF-I-treated group
became obvious, even though there was no signiﬁcant diﬀerence
measurable at day one and three but at day 7. This eﬀect due
to locally applied IGF-I might explain the increased mechanical
stability at day three after surgery, since the increase of connective
tissue was signiﬁcantly higher in the growth factor treated group in
between day one and three, but was not signiﬁcant in the control
groups.
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Figure 6:Reepithelisationofthemucosabecameobviousespecially
at day seven after surgery in all groups, and a tendency of ad-
vanced reepithelisation was seen at this time point in the IGF-I-
treated group. In this group the increase of reepithelisation became
signiﬁcant already in between days one and three and three and
seven, whereas a signiﬁcant diﬀerence in the control groups not
until day seven after surgery occurred.
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Figure 7: Except in the uncoated group in the region of the
anastomosis at day three and day seven, necroses were seen rarely.
Especially the coating and the applied IGF-I did not cause any side
eﬀects which lead to disturbance of the surrounding tissue at any
time point.
The use of coated implants is still some way from being
a standard procedure in surgery. However, the studies that
have so far been performed and initial clinical experience
are promising. Together with progress in the development of
implantsandoperatingtechniquestheycouldhelptofurther
reduce the occurrence of complications in surgery.The Scientiﬁc World Journal 7
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